Nexchip Semiconductor Corporation (688249.SH) has resubmitted its application for an H-share initial public offering to the Hong Kong Stock Exchange and published the application materials.
Crystal Integration (688249.SH) announced that the company has re-submitted the application for the issuance of overseas listed foreign shares (H shares) and listing on the main board of the Hong Kong Stock Exchange to the Hong Kong Stock Exchange on March 31, 2026. The application materials have been published on the website of the Hong Kong Stock Exchange on the same day. The application materials were prepared and published in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange. They are draft versions, and the information contained therein may be updated and revised in a timely manner. Investors should not make any investment decisions based on the information provided in the materials.
Nexchip Semiconductor Corporation (688249.SH) announced that it has re-submitted an application to the Hong Kong Stock Exchange for the issuance of overseas listed foreign shares (H shares) and listing on the main board of the Hong Kong Stock Exchange on March 31, 2026. The company also published the application materials on the Hong Kong Stock Exchange website on the same day. The application materials were prepared and published in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange. The information contained in the application materials is a draft version and may be updated and revised in a timely manner. Investors should not make any investment decisions based on the information contained in the materials.
Related Articles

NEWAY GROUP (00055): Zhang Yushan appointed as the new company secretary.

GLORIOUS PPT H(00845): Property units selling and delivering total construction area exceeding 70,000 square meters in 2025.

SINOMAB BIO-B (03681): The first patient in China with atopic dermatitis completes Phase 2 clinical trial of SM17 treatment.
NEWAY GROUP (00055): Zhang Yushan appointed as the new company secretary.

GLORIOUS PPT H(00845): Property units selling and delivering total construction area exceeding 70,000 square meters in 2025.

SINOMAB BIO-B (03681): The first patient in China with atopic dermatitis completes Phase 2 clinical trial of SM17 treatment.






